| P50 | author | Sek Won Kong | Q58041273 |
| P2093 | author name string | Bob S Carter | |
| | Kwang-Soo Kim | |
| | Jeffrey Schweitzer | |
| | Bin Song | |
| | Nayeon Lee | |
| | Kai-C Sonntag | |
| | Young Cha | |
| | Pierre Leblanc | |
| | Jin Hyuk Jung | |
| | Carolyn Neff | |
| P2860 | cites work | The foxa2 gene controls the birth and spontaneous degeneration of dopamine neurons in old age | Q21090191 |
| | Parkin controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells | Q24304882 |
| | Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells | Q24616059 |
| | Direct conversion of fibroblasts to functional neurons by defined factors | Q24641912 |
| | Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins | Q24653753 |
| | Parkinson's disease gene therapy: success by design meets failure by efficacy | Q26851325 |
| | Generating pluripotent stem cells: differential epigenetic changes during cellular reprogramming | Q27021372 |
| | Treating Parkinson's disease in the 21st century: can stem cell transplantation compete? | Q27024152 |
| | Mesodermal iPSC-derived progenitor cells functionally regenerate cardiac and skeletal muscle | Q27331430 |
| | Stem cells in human neurodegenerative disorders--time for clinical translation? | Q27687068 |
| | Induced pluripotent stem cell lines derived from human somatic cells | Q27860597 |
| | Establishment in culture of pluripotential cells from mouse embryos | Q27860625 |
| | Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors | Q27860937 |
| | Induction of pluripotent stem cells from adult human fibroblasts by defined factors | Q27860967 |
| | Embryonic stem cell lines derived from human blastocysts | Q27861010 |
| | Ten years of induced pluripotency: from basic mechanisms to therapeutic applications | Q28074379 |
| | Diversity matters - heterogeneity of dopaminergic neurons in the ventral mesencephalon and its relation to Parkinson's Disease | Q28078561 |
| | Wnt1-lmx1a forms a novel autoregulatory loop and controls midbrain dopaminergic differentiation synergistically with the SHH-FoxA2 pathway | Q28118756 |
| | Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. | Q28131663 |
| | Generation of clinical-grade human induced pluripotent stem cells in Xeno-free conditions | Q36276275 |
| | Influence of cell preparation and target location on the behavioral recovery after striatal transplantation of fetal dopaminergic neurons in a primate model of Parkinson's disease | Q36326475 |
| | X chromosome reactivation in reprogramming and in development | Q36396148 |
| | Highly efficient and large-scale generation of functional dopamine neurons from human embryonic stem cells. | Q36491400 |
| | Somatic copy number mosaicism in human skin revealed by induced pluripotent stem cells | Q36493686 |
| | Strategy for the creation of clinical grade hESC line banks that HLA-match a target population | Q36602155 |
| | Whole-genome mutational burden analysis of three pluripotency induction methods. | Q36605066 |
| | Amelioration of non-motor dysfunctions after transplantation of human dopamine neurons in a model of Parkinson's disease | Q36709824 |
| | Adult human olfactory epithelial-derived progenitors: a potential autologous source for cell-based treatment for Parkinson's disease | Q36861593 |
| | The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates | Q37003482 |
| | Genetic engineering of mouse embryonic stem cells by Nurr1 enhances differentiation and maturation into dopaminergic neurons. | Q37029659 |
| | Stem cell grafting improves both motor and cognitive impairments in a genetic model of Parkinson's disease, the aphakia (ak) mouse | Q37118996 |
| | Review: Familial Parkinson's disease--genetics, clinical phenotype and neuropathology in relation to the common sporadic form of the disease | Q37151410 |
| | Enhanced yield of neuroepithelial precursors and midbrain-like dopaminergic neurons from human embryonic stem cells using the bone morphogenic protein antagonist noggin. | Q37154197 |
| | Improved cell therapy protocols for Parkinson's disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons | Q37179338 |
| | Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain | Q37183600 |
| | Embryonic stem cell-derived Pitx3-enhanced green fluorescent protein midbrain dopamine neurons survive enrichment by fluorescence-activated cell sorting and function in an animal model of Parkinson's disease | Q37221341 |
| | Human embryonic stem cell-derived dopaminergic neurons reverse functional deficit in parkinsonian rats | Q37255180 |
| | Directed differentiation of dopaminergic neuronal subtypes from human embryonic stem cells. | Q37255219 |
| | Purification of functional human ES and iPSC-derived midbrain dopaminergic progenitors using LRTM1. | Q37345425 |
| | Derivation of midbrain dopamine neurons from human embryonic stem cells | Q37493958 |
| | Induced pluripotent stem cell generation-associated point mutations arise during the initial stages of the conversion of these cells | Q37564317 |
| | Genomic instability in pluripotent stem cells: implications for clinical applications | Q37596254 |
| | Isolation of human induced pluripotent stem cell-derived dopaminergic progenitors by cell sorting for successful transplantation | Q37660450 |
| | Lewy body pathology in fetal grafts | Q37690354 |
| | Cell transplantation in Parkinson's disease: problems and perspectives | Q37758095 |
| | Towards stem cell replacement therapies for Parkinson's disease | Q37759814 |
| | Are synucleinopathies prion-like disorders? | Q37789524 |
| | Genetic and epigenetic stability of human pluripotent stem cells. | Q38042359 |
| | Neuropathology in transplants in Parkinson's disease: implications for disease pathogenesis and the future of cell therapy | Q38063644 |
| | Trophic factor gene therapy for Parkinson's disease | Q38079792 |
| | Cell therapy for Parkinson's disease: what next? | Q38079793 |
| | History, applications, and mechanisms of deep brain stimulation | Q38081354 |
| | Adult subventricular zone neural stem cells as a potential source of dopaminergic replacement neurons | Q38191589 |
| | CRISPR/Cas9-Directed Genome Editing of Cultured Cells | Q38225327 |
| | Long-lasting dyskinesia induced by levodopa | Q42230356 |
| | Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain | Q42280576 |
| | G-Force PD: a global initiative in coordinating stem cell-based dopamine treatments for Parkinson's disease | Q42334406 |
| | IAP-Based Cell Sorting Results in Homogeneous Transplantable Dopaminergic Precursor Cells Derived from Human Pluripotent Stem Cells. | Q42376393 |
| | DNA methylation and transcriptional trajectories during human development and reprogramming of isogenic pluripotent stem cells. | Q42377248 |
| | A simple method for large-scale generation of dopamine neurons from human embryonic stem cells. | Q42845154 |
| | How iPS cells changed the world | Q42993678 |
| | Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease | Q43144355 |
| | Directed dopaminergic neuron differentiation from human pluripotent stem cells | Q43214061 |
| | Effects of immunosuppressive treatment on host responses against intracerebral porcine neural tissue xenografts in rats | Q43675887 |
| | Adrenal medullary transplantation into the brain for treatment of Parkinson's disease: clinical outcome and neurochemical studies | Q43812070 |
| | Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. | Q44037381 |
| | Immune parameters relevant to neural xenograft survival in the primate brain. | Q44282939 |
| | A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease | Q44571920 |
| | Spontaneous Single-Copy Loss of TP53 in Human Embryonic Stem Cells Markedly Increases Cell Proliferation and Survival | Q44597088 |
| | Karotypic abnormalities in human induced pluripotent stem cells and embryonic stem cells | Q45047169 |
| | Elevated coding mutation rate during the reprogramming of human somatic cells into induced pluripotent stem cells | Q45104521 |
| | Differentiation of human embryonic stem cells to dopaminergic neurons in serum-free suspension culture | Q45173531 |
| | Transplantation of human embryonic stem cell-derived neural progenitors improves behavioral deficit in Parkinsonian rats | Q45173532 |
| | Donor-Specific Anti-HLA Antibodies in Huntington's Disease Recipients of Human Fetal Striatal Grafts | Q45296825 |
| | A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency | Q45857796 |
| | Identification of transplantable dopamine neuron precursors at different stages of midbrain neurogenesis. | Q45952942 |
| | Induction of functional dopamine neurons from human astrocytes in vitro and mouse astrocytes in a Parkinson's disease model | Q46056309 |
| | Generating iPSCs: translating cell reprogramming science into scalable and robust biomanufacturing strategies. | Q46115601 |
| | Nuclear transfer embryonic stem cells provide an in vitro culture model for Parkinson's disease. | Q46132065 |
| | To be immunogenic, or not to be: that's the iPSC question | Q46184419 |
| | On the origin of the term "stem cell". | Q46520877 |
| | Induction of human mesenchymal stem cells into dopamine-producing cells with different differentiation protocols | Q46567177 |
| | Primate adult brain cell autotransplantation produces behavioral and biological recovery in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian St. Kitts monkeys | Q46921956 |
| | Cografting astrocytes improves cell therapeutic outcomes in a Parkinson's disease model | Q47262338 |
| | Hotspots of De Novo Point Mutations in Induced Pluripotent Stem Cells. | Q47666594 |
| | Generation of high-purity human ventral midbrain dopaminergic progenitors for in vitro maturation and intracerebral transplantation | Q47734532 |
| | Signs of degeneration in 12-22-year old grafts of mesencephalic dopamine neurons in patients with Parkinson's disease | Q47794452 |
| | Survival of human induced pluripotent stem cell-derived midbrain dopaminergic neurons in the brain of a primate model of Parkinson's disease. | Q47811023 |
| | Electromagnetized gold nanoparticles mediate direct lineage reprogramming into induced dopamine neurons in vivo for Parkinson's disease therapy | Q47888502 |
| | The Parkinson Pandemic-A Call to Action | Q47972031 |
| | Potential Pitfall of Pluripotent Stem Cells | Q48000303 |
| | Human iPS cell-derived dopaminergic neurons function in a primate Parkinson's disease model. | Q48132718 |
| | Maturation of human iPS cell-derived dopamine neuron precursors in alginate-Ca(2+) hydrogel | Q48189107 |
| | Generation of germline-competent induced pluripotent stem cells | Q28131699 |
| | LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1 | Q28210584 |
| | Banking on iPSC--is it doable and is it worthwhile | Q28254023 |
| | Reprogramming of human somatic cells to pluripotency with defined factors | Q28262710 |
| | Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease | Q28275257 |
| | Sheep cloned by nuclear transfer from a cultured cell line | Q28275874 |
| | Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen | Q28283278 |
| | AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial | Q28307713 |
| | Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model | Q28344741 |
| | Wnt antagonism of Shh facilitates midbrain floor plate neurogenesis | Q28505281 |
| | Chemical Control of Grafted Human PSC-Derived Neurons in a Mouse Model of Parkinson's Disease | Q28829174 |
| | Human induced pluripotent stem cells free of vector and transgene sequences | Q29547624 |
| | Epigenetic memory in induced pluripotent stem cells | Q29547892 |
| | Induced pluripotent stem cells from a spinal muscular atrophy patient | Q29614340 |
| | Epidemiology of Parkinson's disease | Q29614901 |
| | Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling | Q29615601 |
| | Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation | Q29615640 |
| | Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease | Q29615682 |
| | A more efficient method to generate integration-free human iPS cells | Q29615748 |
| | Direct generation of functional dopaminergic neurons from mouse and human fibroblasts | Q29616184 |
| | Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome | Q29616636 |
| | Somatic coding mutations in human induced pluripotent stem cells | Q29616798 |
| | Transplantation of embryonic dopamine neurons for severe Parkinson's disease | Q29617304 |
| | Genome sequencing of mouse induced pluripotent stem cells reveals retroelement stability and infrequent DNA rearrangement during reprogramming | Q30413933 |
| | Human embryonic stem cells derived by somatic cell nuclear transfer. | Q30544785 |
| | Efficient generation of human iPSCs by a synthetic self-replicative RNA. | Q30558268 |
| | Adrenal medullary transplant to the striatum of patients with advanced Parkinson's disease: 1-year motor and psychomotor data | Q30570278 |
| | Remote control of induced dopaminergic neurons in parkinsonian rats. | Q30581671 |
| | Increased genomic integrity of an improved protein-based mouse induced pluripotent stem cell method compared with current viral-induced strategies | Q33551989 |
| | Genetic background drives transcriptional variation in human induced pluripotent stem cells | Q33716774 |
| | Preclinical Analysis of Fetal Human Mesencephalic Neural Progenitor Cell Lines: Characterization and Safety In Vitro and In Vivo | Q33722449 |
| | Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency | Q33732735 |
| | The Immunogenicity and Immune Tolerance of Pluripotent Stem Cell Derivatives | Q33753295 |
| | Metabolic requirements for the maintenance of self-renewing stem cells | Q33893346 |
| | Induced neuronal reprogramming | Q33904255 |
| | Induction of midbrain dopaminergic neurons from ES cells by stromal cell-derived inducing activity. | Q33925878 |
| | Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells | Q34019032 |
| | Reprogramming of mouse and human cells to pluripotency using mature microRNAs. | Q34027071 |
| | Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease | Q39519102 |
| | Management of tardive dyskinesia | Q39556122 |
| | Copy number variation and selection during reprogramming to pluripotency | Q39582693 |
| | Memory in Induced Pluripotent Stem Cells: Reprogrammed Human Retinal-Pigmented Epithelial Cells Show Tendency for Spontaneous Redifferentiation | Q39649746 |
| | Glial cell line-derived neurotrophic factor-secreting genetically modified human bone marrow-derived mesenchymal stem cells promote recovery in a rat model of Parkinson's disease | Q39693665 |
| | Robust enhancement of neural differentiation from human ES and iPS cells regardless of their innate difference in differentiation propensity | Q39717297 |
| | Hemangioblastic derivatives from human induced pluripotent stem cells exhibit limited expansion and early senescence | Q39739455 |
| | Dopaminergic neurons derived from human induced pluripotent stem cells survive and integrate into 6-OHDA-lesioned rats | Q39788084 |
| | Reversal of dopaminergic degeneration in a parkinsonian rat following micrografting of human bone marrow-derived neural progenitors | Q39792829 |
| | Induction of adult human bone marrow mesenchymal stromal cells into functional astrocyte-like cells: potential for restorative treatment in Parkinson's disease | Q39898054 |
| | Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson's disease | Q39903811 |
| | Lentiviral delivery of LMX1a enhances dopaminergic phenotype in differentiated human bone marrow mesenchymal stem cells | Q39993972 |
| | Marked differences in differentiation propensity among human embryonic stem cell lines | Q40012772 |
| | Messenger RNA- versus retrovirus-based induced pluripotent stem cell reprogramming strategies: analysis of genomic integrity. | Q40095667 |
| | A protocol for the differentiation of human embryonic stem cells into dopaminergic neurons using only chemically defined human additives: Studies in vitro and in vivo | Q40204992 |
| | Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. | Q40216832 |
| | Differential X Chromosome Inactivation Patterns during the Propagation of Human Induced Pluripotent Stem Cells | Q40369134 |
| | Stromal cell-derived inducing activity, Nurr1, and signaling molecules synergistically induce dopaminergic neurons from mouse embryonic stem cells. | Q40381244 |
| | Dopaminergic differentiation of human embryonic stem cells | Q40493832 |
| | Generation of tyrosine hydroxylase positive neurons from human embryonic stem cells after coculture with cellular substrates and exposure to GDNF. | Q40519699 |
| | Differentiation of embryonic stem cell lines generated from adult somatic cells by nuclear transfer. | Q40809607 |
| | Cell Therapy for Parkinson's Disease: A Translational Approach to Assess the Role of Local and Systemic Immunosuppression. | Q40839095 |
| | Efficient generation of midbrain and hindbrain neurons from mouse embryonic stem cells. | Q40876310 |
| | Induction of a midbrain dopaminergic phenotype in Nurr1-overexpressing neural stem cells by type 1 astrocytes. | Q40942115 |
| | Cryopreservation Maintains Functionality of Human iPSC Dopamine Neurons and Rescues Parkinsonian Phenotypes In Vivo. | Q41018807 |
| | Metabolic control of primed human pluripotent stem cell fate and function by the miR-200c-SIRT2 axis. | Q41271529 |
| | X-linked severe combined immunodeficiency (X-SCID) rats for xeno-transplantation and behavioral evaluation. | Q41463591 |
| | Efficient derivation of functional floor plate tissue from human embryonic stem cells | Q41828883 |
| | Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease. | Q41964090 |
| | Direct comparison of autologous and allogeneic transplantation of iPSC-derived neural cells in the brain of a non-human primate | Q42072961 |
| | Striatal Transplantation of Human Dopaminergic Neurons Differentiated From Induced Pluripotent Stem Cells Derived From Umbilical Cord Blood Using Lentiviral Reprogramming | Q42180819 |
| | Are Stem Cell-Based Therapies for Parkinson's Disease Ready for the Clinic in 2016? | Q35966394 |
| | Quantification of Retinogenesis in 3D Cultures Reveals Epigenetic Memory and Higher Efficiency in iPSCs Derived from Rod Photoreceptors | Q35990735 |
| | Immune problems in central nervous system cell therapy. | Q36045396 |
| | Stem cells may reshape the prospect of Parkinson's disease therapy. | Q36080015 |
| | Specification of midbrain dopamine neurons from primate pluripotent stem cells | Q36117009 |
| | Donor-dependent variations in hepatic differentiation from human-induced pluripotent stem cells | Q36140488 |
| | Predictive Markers Guide Differentiation to Improve Graft Outcome in Clinical Translation of hESC-Based Therapy for Parkinson's Disease | Q36250893 |
| | Low incidence of DNA sequence variation in human induced pluripotent stem cells generated by nonintegrating plasmid expression | Q34030950 |
| | An integrative analysis of reprogramming in human isogenic system identified a clone selection criterion. | Q34046292 |
| | Effect of human donor cell source on differentiation and function of cardiac induced pluripotent stem cells | Q34053605 |
| | Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats | Q34115609 |
| | Differentiation of human ES and Parkinson's disease iPS cells into ventral midbrain dopaminergic neurons requires a high activity form of SHH, FGF8a and specific regionalization by retinoic acid. | Q34156273 |
| | Genetic correction and analysis of induced pluripotent stem cells from a patient with gyrate atrophy. | Q34175757 |
| | Passage number is a major contributor to genomic structural variations in mouse iPSCs | Q34195138 |
| | Epigenetic memory and preferential lineage-specific differentiation in induced pluripotent stem cells derived from human pancreatic islet beta cells | Q34197304 |
| | Donor cell type can influence the epigenome and differentiation potential of human induced pluripotent stem cells | Q34236195 |
| | Inhibition of pluripotent stem cell-derived teratoma formation by small molecules | Q34362039 |
| | Efficient generation of functional dopaminergic neurons from human induced pluripotent stem cells under defined conditions | Q34373911 |
| | Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. | Q34416128 |
| | RIKEN suspends first clinical trial involving induced pluripotent stem cells | Q34493074 |
| | Human ESC-derived dopamine neurons show similar preclinical efficacy and potency to fetal neurons when grafted in a rat model of Parkinson's disease | Q34515645 |
| | Induced Pluripotent Stem Cells Meet Genome Editing | Q34525438 |
| | Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports | Q34530719 |
| | Autologous Induced Stem-Cell-Derived Retinal Cells for Macular Degeneration. | Q34553328 |
| | Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture | Q34596358 |
| | Reference Maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines | Q34714112 |
| | Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years | Q34768147 |
| | Local control of the host immune response performed with mesenchymal stem cells: perspectives for functional intracerebral xenotransplantation | Q34885388 |
| | Rapid induction and long-term self-renewal of primitive neural precursors from human embryonic stem cells by small molecule inhibitors | Q35002960 |
| | Protein-based human iPS cells efficiently generate functional dopamine neurons and can treat a rat model of Parkinson disease | Q35015732 |
| | ES cell-derived renewable and functional midbrain dopaminergic progenitors. | Q35034938 |
| | A comparison of non-integrating reprogramming methods | Q35087542 |
| | Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors | Q35180600 |
| | Alloimmunisation to donor antigens and immune rejection following foetal neural grafts to the brain in patients with Huntington's disease | Q35575249 |
| | Effects of Integrating and Non-Integrating Reprogramming Methods on Copy Number Variation and Genomic Stability of Human Induced Pluripotent Stem Cells | Q35679665 |
| | Cell-based therapies for Parkinson disease—past insights and future potential | Q35736662 |
| | Human induced pluripotent stem cells in Parkinson's disease: A novel cell source of cell therapy and disease modeling | Q35789181 |
| | Genetic Variability Overrides the Impact of Parental Cell Type and Determines iPSC Differentiation Potential | Q35896332 |
| | Genetic Variation, Not Cell Type of Origin, Underlies the Majority of Identifiable Regulatory Differences in iPSCs | Q35905022 |
| | Recurrent variations in DNA methylation in human pluripotent stem cells and their differentiated derivatives. | Q35947502 |
| | Sequential bilateral transplantation in Parkinson's disease: effects of the second graft | Q48194358 |
| | Transplantation in Parkinson's disease: two cases of adrenal medullary grafts to the putamen | Q48200600 |
| | Nigral grafts in animal models of Parkinson's disease. Is recovery beyond motor function possible? | Q48274245 |
| | Idiopathic Parkinson's disease patient-derived induced pluripotent stem cells function as midbrain dopaminergic neurons in rodent brains. | Q48294409 |
| | Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease | Q48405897 |
| | Generation of regionally specified neural progenitors and functional neurons from human embryonic stem cells under defined conditions | Q48435042 |
| | Origin-dependent neural cell identities in differentiated human iPSCs in vitro and after transplantation into the mouse brain. | Q48543745 |
| | Co-administration of adenovirus vector expressing CTLA4-Ig prolongs transgene expression in the brain of mice sensitized with adenovirus | Q48913603 |
| | Converting human skin cells to neurons: a new tool to study and treat brain disorders? | Q48922209 |
| | Human Trials of Stem Cell-Derived Dopamine Neurons for Parkinson's Disease: Dawn of a New Era. | Q50183713 |
| | Neurotrophic factor expression in expandable cell populations from brain samples in living patients with Parkinson's disease. | Q50859562 |
| | An efficient method for the derivation of mouse embryonic stem cells. | Q51306983 |
| | Polar Extremes in the Clinical Use of Stem Cells. | Q52781958 |
| | Human embryonic stem cell-derived neural precursors as a continuous, stable, and on-demand source for human dopamine neurons. | Q53562546 |
| | Parkinson's disease | Q54072241 |
| | Small-molecule inhibitors of bone morphogenic protein and activin/nodal signals promote highly efficient neural induction from human pluripotent stem cells. | Q54397059 |
| | Trials of embryonic stem cells to launch in China | Q59080264 |
| | Lewy body pathology in long-term fetal nigral transplants: is Parkinson's disease transmitted from one neural system to another? | Q64876440 |
| | Functional fetal nigral grafts in a patient with Parkinson's disease: chemoanatomic, ultrastructural, and metabolic studies | Q67243403 |
| | Transplantation of human embryonic stem cell-derived cells to a rat model of Parkinson's disease: effect of in vitro differentiation on graft survival and teratoma formation | Q82927480 |
| | Etiology and pathogenesis of Parkinson's disease | Q84231134 |
| | Directed differentiation of dopamine neurons from human pluripotent stem cells | Q84712134 |
| | Deep-brain stimulation for Parkinson's disease | Q85211794 |
| | Developing dopaminergic cell therapy for Parkinson's disease--give up or move forward? | Q86096962 |
| | Concise review: Genomic instability in human stem cells: current status and future challenges. | Q38235527 |
| | Do human leukocyte antigen-typed cellular therapeutics based on induced pluripotent stem cells make commercial sense? | Q38253146 |
| | Direct lineage reprogramming: strategies, mechanisms, and applications | Q38346530 |
| | The prion hypothesis of Parkinson's disease | Q38418624 |
| | How to make a midbrain dopaminergic neuron | Q38503992 |
| | In vitro and in vivo analyses of human embryonic stem cell-derived dopamine neurons | Q38515054 |
| | Temporally controlled modulation of FGF/ERK signaling directs midbrain dopaminergic neural progenitor fate in mouse and human pluripotent stem cells | Q38536402 |
| | Cell therapy for Parkinson's disease: Functional role of the host immune response on survival and differentiation of dopaminergic neuroblasts | Q38560345 |
| | Clinical translation of stem cell transplantation in Parkinson's disease | Q38579206 |
| | Direct somatic lineage conversion | Q38594907 |
| | MHC matching improves engraftment of iPSC-derived neurons in non-human primates | Q38635387 |
| | Strategies for bringing stem cell-derived dopamine neurons to the clinic: A European approach (STEM-PD). | Q38677985 |
| | Variability of human pluripotent stem cell lines. | Q38694107 |
| | Human pluripotent stem cells recurrently acquire and expand dominant negative P53 mutations | Q38705984 |
| | A decade of transcription factor-mediated reprogramming to pluripotency | Q38736148 |
| | Pluripotent stem cells progressing to the clinic | Q38747535 |
| | Incomplete DNA methylation underlies a transcriptional memory of somatic cells in human iPS cells. | Q38771932 |
| | A New, Dynamic Era for Somatic Cell Nuclear Transfer? | Q38818717 |
| | Brain repair and reprogramming: the route to clinical translation. | Q38829948 |
| | Looking to the future following 10 years of induced pluripotent stem cell technologies | Q38834610 |
| | Evaluating cell reprogramming, differentiation and conversion technologies in neuroscience | Q38838046 |
| | Fail-Safe Therapy by Gamma-Ray Irradiation Against Tumor Formation by Human-Induced Pluripotent Stem Cell-Derived Neural Progenitors | Q38883920 |
| | Molecular Obstacles to Clinical Translation of iPSCs | Q38906911 |
| | Genomic Instability of iPSCs: Challenges Towards Their Clinical Applications | Q38945910 |
| | iPSCs and fibroblast subclones from the same fibroblast population contain comparable levels of sequence variations. | Q38975316 |
| | Neural Subtype Specification from Human Pluripotent Stem Cells | Q38998787 |
| | Human induced pluripotent stem cell-derived neurons improve motor asymmetry in a 6-hydroxydopamine-induced rat model of Parkinson's disease | Q39031960 |
| | Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease | Q39116027 |
| | Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson's disease | Q39235649 |
| | Neural grafting for Parkinson's disease: challenges and prospects. | Q39282063 |
| | Factors affecting the clinical outcome after neural transplantation in Parkinson's disease | Q39360071 |
| | Prolonged maturation culture favors a reduction in the tumorigenicity and the dopaminergic function of human ESC-derived neural cells in a primate model of Parkinson's disease | Q39397495 |
| | Assessing the Safety of Human Pluripotent Stem Cells and Their Derivatives for Clinical Applications. | Q39430919 |
| | Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient | Q39434658 |
| P921 | main subject | pluripotency | Q1894941 |
| | Parkinson's disease | Q11085 |
| P304 | page(s) | 1-20 | |
| P577 | publication date | 2018-04-11 | |
| P1433 | published in | Progress in Neurobiology | Q15716615 |
| P1476 | title | Pluripotent stem cell-based therapy for Parkinson's disease: Current status and future prospects | |
| P478 | volume | 168 | |